Szakács Gergely, Paterson Jill K, Ludwig Joseph A, Booth-Genthe Catherine, Gottesman Michael M
Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest Karolina út 29; H-1518 Hungary.
Nat Rev Drug Discov. 2006 Mar;5(3):219-34. doi: 10.1038/nrd1984.
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
转移性癌症的有效治疗通常需要使用毒性化疗药物。在大多数情况下,会使用多种药物,因为几乎普遍会出现对单一药物的耐药性。因此,阐明赋予对具有不同靶点和化学结构的不同药物同时耐药的机制——多药耐药性——在过去35年里一直是癌症生物学家的主要目标。在此,我们综述这些最常见的机制,其中一种依赖于由ATP结合盒(ABC)转运蛋白介导的癌细胞药物外排。我们描述了对抗多药耐药性癌症的各种方法,包括开发能够作用于、规避或利用ABC转运蛋白介导的外排的药物。